In the quest to overhaul the approach to cancer screening, Emi Gal, founder of Ezra, is leveraging AI to make MRI technology faster, more accurate and widely accessible. Gal, who has a personal connection to cancer’s impact, predicts a future where early detection becomes routine, affordable, and lifesaving.
“The cure for cancer,” he explained during a recent interview, “is early detection,” a concept that guided him in founding Ezra, a company focused on full-body cancer screening through AI-enhanced MRI scans.
Gal’s innovation centers around a full-body MRI powered by AI, screening for cancer in 13 organs beyond those typically examined.
“In today’s system, screening only exists for six organs, which accounts for just half of cancer cases by incidence,” he said, noting the limitations and expense of traditional MRI technology. Ezra’s AI tools, however, aim to bridge this gap. “Our AIs reduce MRI scan time by 50%, which in turn lowers the costs,” Gal noted, adding that the reduction in time makes these scans more financially accessible for a broader population.
At Ezra, AI plays a critical role in each step of the screening process, enhancing efficiency and accuracy. As Gal put it: “Our first AI makes scans faster; our second AI, Ezra Assist, helps radiologists by automating measurements, and the third AI translates complex radiology reports into plain language for patients.” These improvements do more than just lower costs; they address concerns about incidental findings and false positives, which can lead to unnecessary follow-ups. With AI streamlining diagnostics, Gal believes Ezra’s approach can mitigate these issues and offer a reliable screening option for millions.
The medical landscape, however, presents its own challenges. Gal observed: “Healthcare today is ‘sick care,’ not ‘healthcare,’ especially in the U.S.,” as treatments are often costly, reactive responses rather than proactive measures. Ezra’s mission of direct-to-consumer screening aims to shift this paradigm, making routine early detection available to the general public.
“When people can access screenings early, the potential for survival increases drastically,” said Gal. Through AI, Gal hopes Ezra’s screenings can serve as a preventative measure, catching cancer before it progresses to a late stage.
Despite the technological advances, the human element remains central to Ezra’s process. While AI enhances efficiency and accuracy, radiologists still provide context and deeper insights into each scan. “AI can show the ‘what,’ while the radiologist explains the ‘why,’” Gal said. Rather than replacing human expertise, he sees AI as a powerful tool for assisting radiologists and making care more accessible, especially given the shortage of MRI specialists.
With investors like Bryan Johnson helping expand Ezra’s reach and costs potentially dropping further, Gal envisions a future where these screenings become as routine as an annual checkup.
“Every year, 10 million people are diagnosed with cancer late. If we could detect it early for everyone, we’d save 6 million lives each year,” Gal reflected. Through Ezra, he hopes to not only tackle cancer on a global scale but also redefine what healthcare can be in the age of AI-driven diagnostics.
